Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The Lancet,
22h
Healthier Together: New GLP-1 drugs can change relationships
Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...
Hosted on MSN
3d
Looking To Come Off GLP-1 Injectables? Try Calocurb, a Natural Appetite Suppressant, Instead!
Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.
Medscape
1d
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
FiercePharma
2d
Nephrologists already aboard GLP-1 bandwagon, providing launchpad for Ozempic in CKD: Spherix
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
HealthDay on MSN
10h
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
Hosted on MSN
2d
GLP-1 Trends by CivicScience: GLP-1 Users Foresee Long-Term Use, Spending More on Clothing and Groceries, Plus More
This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
News Medical on MSN
15h
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
Healio
2d
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
WPSD Local 6
1d
The benefits and risks of GLP-1 drugs
They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...
2d
Whose cardiovascular health do SGLT2, GLP-1 diabetes drugs benefit most?
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
Medscape
10d
GLP-1 for Complex Cases: Breakthrough Therapies That Transform Patient Care
Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...
4d
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Parkinson's disease
Novo Nordisk
Food and Drug Administration
Feedback